Neutralization of ARCoV-induced sera against SARS-CoV-2 variants
ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2094142 |
| _version_ | 1797673172800110592 |
|---|---|
| author | Xiao-Feng Li Na-Na Zhang Yu-Hua Li Shou-Chun Cao Yi-Fei Zhang Cheng-Feng Qin |
| author_facet | Xiao-Feng Li Na-Na Zhang Yu-Hua Li Shou-Chun Cao Yi-Fei Zhang Cheng-Feng Qin |
| author_sort | Xiao-Feng Li |
| collection | DOAJ |
| description | ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102). Here, we tested the cross-neutralization against SARS-CoV-2 variants of concern (VOCs) of a panel of serum samples from participants in the phase 1 clinical trial of ARCoV by pesudo- and authentic SARS-CoV-2. Our data suggest the immunity induced by the ARCoV vaccine reduced but still has significant neutralization against the Alpha and Delta variants. Moreover, ARCoV maintained activity against the Beta variant, despite of its obvious reduction in neutralizing titers. Our findings further support the solid protective neutralization activity against VOCs induced by ARCoV vaccine. |
| first_indexed | 2024-03-11T21:41:04Z |
| format | Article |
| id | doaj.art-d299d494eb5c4ab2941b5449ee123fa8 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:04Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-d299d494eb5c4ab2941b5449ee123fa82023-09-26T13:19:08ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.20941422094142Neutralization of ARCoV-induced sera against SARS-CoV-2 variantsXiao-Feng Li0Na-Na Zhang1Yu-Hua Li2Shou-Chun Cao3Yi-Fei Zhang4Cheng-Feng Qin5Academy of Military Medical SciencesAcademy of Military Medical SciencesNational Institutes for Food and Drug ControlNational Institutes for Food and Drug ControlAcademy of Military Medical SciencesAcademy of Military Medical SciencesARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102). Here, we tested the cross-neutralization against SARS-CoV-2 variants of concern (VOCs) of a panel of serum samples from participants in the phase 1 clinical trial of ARCoV by pesudo- and authentic SARS-CoV-2. Our data suggest the immunity induced by the ARCoV vaccine reduced but still has significant neutralization against the Alpha and Delta variants. Moreover, ARCoV maintained activity against the Beta variant, despite of its obvious reduction in neutralizing titers. Our findings further support the solid protective neutralization activity against VOCs induced by ARCoV vaccine.http://dx.doi.org/10.1080/21645515.2022.2094142sars-cov-2mrna vaccinearcovvariants of concernneutralization |
| spellingShingle | Xiao-Feng Li Na-Na Zhang Yu-Hua Li Shou-Chun Cao Yi-Fei Zhang Cheng-Feng Qin Neutralization of ARCoV-induced sera against SARS-CoV-2 variants Human Vaccines & Immunotherapeutics sars-cov-2 mrna vaccine arcov variants of concern neutralization |
| title | Neutralization of ARCoV-induced sera against SARS-CoV-2 variants |
| title_full | Neutralization of ARCoV-induced sera against SARS-CoV-2 variants |
| title_fullStr | Neutralization of ARCoV-induced sera against SARS-CoV-2 variants |
| title_full_unstemmed | Neutralization of ARCoV-induced sera against SARS-CoV-2 variants |
| title_short | Neutralization of ARCoV-induced sera against SARS-CoV-2 variants |
| title_sort | neutralization of arcov induced sera against sars cov 2 variants |
| topic | sars-cov-2 mrna vaccine arcov variants of concern neutralization |
| url | http://dx.doi.org/10.1080/21645515.2022.2094142 |
| work_keys_str_mv | AT xiaofengli neutralizationofarcovinducedseraagainstsarscov2variants AT nanazhang neutralizationofarcovinducedseraagainstsarscov2variants AT yuhuali neutralizationofarcovinducedseraagainstsarscov2variants AT shouchuncao neutralizationofarcovinducedseraagainstsarscov2variants AT yifeizhang neutralizationofarcovinducedseraagainstsarscov2variants AT chengfengqin neutralizationofarcovinducedseraagainstsarscov2variants |